Neupharma announces the positive conclusion of the phase 1 study, conducted at the “Azienda Ospedaliera Universitaria Integrata” of Verona, with the formulation of inhaled teicoplanin in CF patients.
The Food and Drug Administration has granted the Pediatric Orphan Drug Designation to the inhaled formulation of Teicoplanin for patients with Cystic Fibrosis.
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula for cystic fibrosis, a formula developed by Neupharma in collaboration with the non-profit company Rare Partners.
